EUR 138.8
(-0.86%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 114.38 Thousand EUR | 2263.59% |
2022 | -5287.00 EUR | -100.34% |
2021 | 1.53 Million EUR | -31.79% |
2020 | 2.24 Million EUR | -99.21% |
2019 | 284.88 Million EUR | 29855.84% |
2018 | 951 Thousand EUR | 1.17% |
2017 | 940 Thousand EUR | 38.85% |
2016 | 677 Thousand EUR | 13.97% |
2015 | 594 Thousand EUR | -8.33% |
2014 | 648 Thousand EUR | -20.3% |
2013 | 813 Thousand EUR | 94.5% |
2012 | 418 Thousand EUR | 12.37% |
2011 | 372 Thousand EUR | 1.92% |
2010 | 365 Thousand EUR | -7.83% |
2009 | 396 Thousand EUR | 178.11% |
2008 | -507 Thousand EUR | -397.06% |
2007 | -102 Thousand EUR | -109.6% |
2006 | 1.06 Million EUR | -24.13% |
2005 | 1.4 Million EUR | 283.84% |
2004 | 365 Thousand EUR | -96.59% |
2003 | 10.69 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 20.51 Thousand EUR | 0.0% |
2023 Q4 | 900.65 Thousand EUR | 0.0% |
2023 Q2 | 258.38 Thousand EUR | 0.0% |
2023 FY | 254.98 Thousand EUR | 4922.87% |
2022 FY | -5287.00 EUR | -100.34% |
2022 Q2 | 144.47 Million EUR | 0.0% |
2022 Q4 | 144.51 Million EUR | 0.0% |
2021 Q2 | 205.17 Million EUR | 0.0% |
2021 FY | 1.53 Million EUR | -31.79% |
2021 Q4 | 205.22 Million EUR | 0.0% |
2020 Q4 | 130.99 Million EUR | 0.0% |
2020 FY | 2.24 Million EUR | -99.21% |
2020 Q2 | 129.94 Million EUR | 0.0% |
2019 FY | 284.88 Million EUR | 29855.84% |
2019 Q2 | 547 Thousand EUR | 0.0% |
2019 Q4 | 136.98 Million EUR | 0.0% |
2018 FY | 951 Thousand EUR | 1.17% |
2018 Q1 | 50.5 Thousand EUR | -99.96% |
2018 Q4 | 88.35 Million EUR | 0.0% |
2018 Q2 | 198.91 Million EUR | 393781.19% |
2017 Q2 | 155.06 Million EUR | 319627.84% |
2017 FY | 940 Thousand EUR | 38.85% |
2017 Q4 | 115.71 Million EUR | 0.0% |
2017 Q1 | 48.5 Thousand EUR | -99.94% |
2016 FY | 677 Thousand EUR | 13.97% |
2016 Q4 | 77.34 Million EUR | 0.0% |
2016 Q2 | 108.35 Million EUR | 734523.73% |
2016 Q1 | 14.75 Thousand EUR | -99.99% |
2015 FY | 594 Thousand EUR | -8.33% |
2015 Q3 | 25.75 Thousand EUR | -99.97% |
2015 Q4 | 130.68 Million EUR | 507418.45% |
2015 Q2 | 86.82 Million EUR | 337080.58% |
2015 Q1 | 25.75 Thousand EUR | -99.89% |
2014 Q4 | 23.48 Million EUR | 67488.49% |
2014 FY | 648 Thousand EUR | -20.3% |
2014 Q3 | 34.75 Thousand EUR | -99.92% |
2014 Q1 | 34.75 Thousand EUR | -99.9% |
2014 Q2 | 46 Million EUR | 132282.73% |
2013 Q2 | 20.18 Million EUR | 39667.49% |
2013 Q1 | 50.75 Thousand EUR | 0.0% |
2013 Q4 | 36.14 Million EUR | 71115.76% |
2013 Q3 | 50.75 Thousand EUR | -99.75% |
2013 FY | 813 Thousand EUR | 94.5% |
2012 Q1 | 53.25 Thousand EUR | 0.0% |
2012 FY | 418 Thousand EUR | 12.37% |
2012 Q3 | 53.25 Thousand EUR | 0.0% |
2012 Q4 | 50.75 Thousand EUR | -4.69% |
2012 Q2 | 53.25 Thousand EUR | 0.0% |
2011 Q3 | 61 Thousand EUR | 0.0% |
2011 FY | 372 Thousand EUR | 1.92% |
2011 Q4 | 53.25 Thousand EUR | -12.7% |
2011 Q2 | 61 Thousand EUR | 0.0% |
2011 Q1 | 61 Thousand EUR | 0.0% |
2010 Q4 | 61 Thousand EUR | 31.89% |
2010 Q1 | 46.25 Thousand EUR | 0.0% |
2010 FY | 365 Thousand EUR | -7.83% |
2010 Q3 | 46.25 Thousand EUR | 0.0% |
2010 Q2 | 46.25 Thousand EUR | 0.0% |
2009 Q4 | 46.25 Thousand EUR | -19.21% |
2009 Q1 | 57.25 Thousand EUR | 0.0% |
2009 Q2 | 57.25 Thousand EUR | 0.0% |
2009 FY | 396 Thousand EUR | 178.11% |
2009 Q3 | 57.25 Thousand EUR | 0.0% |
2008 Q1 | -148.25 Thousand EUR | 0.0% |
2008 Q3 | -148.25 Thousand EUR | 0.0% |
2008 Q2 | -148.25 Thousand EUR | 0.0% |
2008 Q4 | 57.25 Thousand EUR | 138.62% |
2008 FY | -507 Thousand EUR | -397.06% |
2007 Q2 | -45.25 Thousand EUR | 0.0% |
2007 Q4 | -148.25 Thousand EUR | -227.62% |
2007 Q1 | -45.25 Thousand EUR | 0.0% |
2007 Q3 | -45.25 Thousand EUR | 0.0% |
2007 FY | -102 Thousand EUR | -109.6% |
2006 Q1 | 188.5 Thousand EUR | 0.0% |
2006 Q2 | 188.5 Thousand EUR | 0.0% |
2006 Q3 | 188.5 Thousand EUR | 0.0% |
2006 Q4 | -45.25 Thousand EUR | -124.01% |
2006 FY | 1.06 Million EUR | -24.13% |
2005 FY | 1.4 Million EUR | 283.84% |
2005 Q4 | 188.5 Thousand EUR | 42.26% |
2005 Q3 | 132.5 Thousand EUR | 0.0% |
2005 Q2 | 132.5 Thousand EUR | 0.0% |
2005 Q1 | 132.5 Thousand EUR | 0.0% |
2004 Q4 | 132.5 Thousand EUR | 115.45% |
2004 Q2 | 61.5 Thousand EUR | 0.0% |
2004 Q3 | 61.5 Thousand EUR | 0.0% |
2004 Q1 | 61.5 Thousand EUR | 0.0% |
2004 FY | 365 Thousand EUR | -96.59% |
2003 Q3 | 29.54 Million EUR | 0.0% |
2003 FY | 10.69 Million EUR | 0.0% |
2003 Q2 | 29.54 Million EUR | 0.0% |
2003 Q1 | 29.54 Million EUR | 0.0% |
2003 Q4 | 61.5 Thousand EUR | -99.79% |
2002 Q4 | 29.54 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | 97.261% |
ABIVAX Société Anonyme | 127.37 Million EUR | 99.91% |
Adocia SA | 15.62 Million EUR | 99.268% |
Aelis Farma SA | 18.81 Million EUR | 99.392% |
Biophytis S.A. | 14.33 Million EUR | 99.202% |
Advicenne S.A. | 8.21 Million EUR | 98.608% |
genOway Société anonyme | 16.73 Million EUR | 99.317% |
IntegraGen SA | 5.35 Million EUR | 97.863% |
Medesis Pharma S.A. | 1.56 Million EUR | 92.689% |
Neovacs S.A. | 10.34 Million EUR | 98.894% |
NFL Biosciences SA | 4.37 Million EUR | 97.385% |
Plant Advanced Technologies SA | 2.76 Million EUR | 95.863% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | 93.342% |
Sensorion SA | 27.05 Million EUR | 99.577% |
Theranexus Société Anonyme | 3 Million EUR | 96.193% |
TME Pharma N.V. | 5.49 Million EUR | 97.919% |
Valbiotis SA | 9.86 Million EUR | 98.841% |
TheraVet SA | 1.64 Million EUR | 93.043% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | 99.437% |
argenx SE | 1.34 Billion EUR | 99.991% |
BioSenic S.A. | 7.58 Million EUR | 98.492% |
Celyad Oncology SA | 8.49 Million EUR | 98.653% |
DBV Technologies S.A. | 89.4 Million EUR | 99.872% |
Galapagos NV | 327.98 Million EUR | 99.965% |
Genfit S.A. | 54.8 Million EUR | 99.791% |
GeNeuro SA | 14.35 Million EUR | 99.203% |
Hyloris Pharmaceuticals SA | 17.98 Million EUR | 99.364% |
Innate Pharma S.A. | 64.57 Million EUR | 99.823% |
Inventiva S.A. | 120.18 Million EUR | 99.905% |
MaaT Pharma SA | 21.59 Million EUR | 99.47% |
MedinCell S.A. | 32.92 Million EUR | 99.653% |
Nanobiotix S.A. | 58.92 Million EUR | 99.806% |
Onward Medical N.V. | 20.64 Million EUR | 99.446% |
Oryzon Genomics S.A. | 18.49 Million EUR | 99.382% |
OSE Immunotherapeutics SA | 23.58 Million EUR | 99.515% |
Oxurion NV | 12.21 Million EUR | 99.063% |
Pharming Group N.V. | 204.24 Million EUR | 99.944% |
Poxel S.A. | 28.76 Million EUR | 99.602% |
GenSight Biologics S.A. | 32.66 Million EUR | 99.65% |
Transgene SA | 31.23 Million EUR | 99.634% |
UCB SA | 2.94 Billion EUR | 99.996% |
Valneva SE | 134.92 Million EUR | 99.915% |
Vivoryon Therapeutics N.V. | 24.69 Million EUR | 99.537% |